Rentz, Dorene M.
Mormino, Elizabeth C.
Papp, Kathryn V.
Betensky, Rebecca A.
Sperling, Reisa A.
Johnson, Keith A.
Funding for this research was provided by:
National Institute on Aging (P01 AG036694, R01 AG037497, R01EB014894,)
Alzheimer's Association (IIRG-08-90934)
Article History
First Online: 13 October 2016
Compliance with ethical standards
:
: All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: The National Institute on Aging (P01 AG036694, RO1 AG037497, RO1EB014894) and the Alzheimer’s Association IIRG-08-90,934 funded this study.
: D. Rentz received research support from the NIH grants P01 AG036694, R01 MH090291, U01 AG024904, R01 AG027435, R01 AG037497 and P50 AG005134, Alzheimer Association grant IIRG-08-90,934 and Fidelity Biosciences. She has also served as a paid consultant for Eli Lilly, Lundbeck Pharmaceuticals, Janssen Alzheimer Immunotherapy, Biogen, Idec and Neurotrack. These relationships are not related to the content in the manuscript.E. Mormino received funding from NIH grant F32AG044054 and P01 AG036694 and has served as a paid consultant for Janssen Pharmaceuticals and Biogen Idec. These relationships are not related to the content in the manuscript.K. Papp was supported by NIA grant T32AG023480–08, the Charles King Trust, and NIH grant P01 AG036694 and has served as a paid consultant for Biogen Idec. These relationships are not related to the content in the manuscript.R. Betensky received funding from NIH grants R01 CA075971, R03 CA165070, UL 1RR025758, P50 NS051343, P50 NS051343, P30 CA006516, P50 AG005134, P01 AG036694, R01 NS070834, R01 NS070834 and R01 AG026484.R. Sperling has served as a paid consultant for Abbvie, Biogen, Bracket, Genentech, Lundbeck, Roche, and Sanofi. She has served as a co-investigator for Avid, Eli Lilly, and Janssen Alzheimer Immunotherapy clinical trials. She has spoken at symposia sponsored by Eli Lilly, Biogen, and Janssen. R. Sperling receives research support from Janssen Pharmaceuticals, and Eli Lilly and Co. These relationships are not related to the content in the manuscript. She also receives research support from the following grants: P01 AG036694, U01 AG032438, U01 AG024904, R01 AG037497, R01 AG034556, K24 AG035007, P50 AG005134, U19 AG010483, R01 AG027435, Fidelity Biosciences, Harvard NeuroDiscovery Center, and the Alzheimer’s Association.K. Johnson has served as paid consultant for Bayer, Bristol-Myers Squibb, GE Healthcare, Janssen Alzheimer’s Immunotherapy, Siemens Medical Solutions, and Genzyme. He is a site coinvestigator for Lilly/Avid, Bristol-Myers Squibb, Pfizer, Janssen Immunotherapy, and Navidea. He has spoken at symposia sponsored by Janssen Alzheimer’s Immunotherapy and Pfizer. T. Benzinger has served on an advisory board for Eli Lilly and has received research funding from Avid Radiopharmaceuticals. These relationships are not related to the content in the manuscript. K. Johnson receives funding from NIH grants R01EB014894, R21 AG038994, R01 AG026484, R01 AG034556, P50 AG00513421, U19 AG10483, P01 AG036694, R13 AG042201174210, R01 AG027435, and R01 AG037497 and the Alzheimer’s Association grant ZEN-10-174,210.